Close
Close

Anti-BSLF2/BMLF1 T cell receptor (AS01), pCDTCR1 (TCR-YC0141)

 Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The archetypal AS01 TCR is likely to be one of the most common and numerically frequent αβ TCRs in humans. This is based on the following considerations: (i) the HLA-A*0201 allele is arguably the most common and widespread MHC-I allele in humans, with frequencies above 60% in certain regions; (ii) EBV is one of the most successfully disseminated human pathogens, persistently infecting more than 90% of individuals; (iii) the GLC-A2 antigen is one of the most immunodominant CD8+ T cell targets across the EBV proteome; (iv) GLC-specific CD8+ T cell responses are amongst the largest observed, both in the EBV system and in comparative terms with respect to other human pathogens studied thus far; and, (v) the GLC-specific response is dominated by CD8+ T cells that bear a public TRAV5/TRBV20-1 receptor.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • BSLF2/BMLF1
  • Target Species
  • EBV
  • Epitope
  • GLCTLVAML
  • Format
  • Non-Modified TCR
  • Allele
  • HLA-A
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • AS01
  • Host Species
  • Human

Target

  • Introduction
  • Epstein-Barr virus (EBV), also called human herpesvirus 4 (HHV-4), is a genetically stable agent that has slowly co-evolved with our species and its antecedents for millions of years. EBV is typically transmitted orally during childhood, propagates in B cells and epithelia, and is shed for the lifetime of the host. More than 90% of the world's population is infected with EBV. This mutual coexistence is not without heavy resource cost for the host. Large populations of CD8+ αβ T lymphocytes are deployed for the purposes of EBV surveillance and suppression. These populations peak during asymptomatic primary infection, acute infectious mononucleosis (AIM) and old age. Across the entire EBV proteome, one of the most immunogenic CD8+ T cell targets is the HLA-A*0201-restricted GLCTLVAML peptide derived from the BMLF1 protein (residues 280–288; herein referred to as GLC-A2). During primary infection, up to 11% of the total peripheral CD8+ T cell pool can be specific for GLC-A2; this response contracts to 0.5–2.2% of the peripheral CD8+ T cell pool during persistent infection, but can swell again to 10% in old age. Given the high in vivo frequencies of this response and the ubiquity of both EBV infection and the HLA-A*0201 allele, it is unsurprising that GLC-A2 is one of the most studied HLA class-I target antigens. Interestingly, initial investigations into the clonotypic nature of the GLC-A2 response revealed that CD8+ T cells are deployed with a biased T cell receptor (TCR) repertoire that is stable over time.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-BSLF2/BMLF1 T cell receptor (AS01), pCDTCR1 (TCR-YC0141). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

TCR Vector Products

Viral Infection

Breast cancer

Lung malignancy

Others

Prostate cancer

Melanoma

Autoimmune Diseases

Acute lymphoblastic leukemia (ALL)

Hepatoblastoma

Colorectal cancer

Online Inquiry
Products
Global Services
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.
Copyright © 2024 Creative Biolabs. All Rights Reserved
Cart
    Go to checkout